The Banner Alzheimer's Institute Case Conference is a weekly event in which physicians and staff discuss challenging and/or teaching cases of patients seen at the Institute's Stead Family Memory Clinic. These conferences are attended by a multidisciplinary group that includes Banner Alzheimer's Institute dementia specialists, community physicians (internal medicine, family medicine, and radiology), physician assistants, social workers, nurses, medical students, residents, and fellows. The Banner Alzheimer's Institute located in Phoenix, Arizona, has an unusually ambitious mission: to end Alzheimer's disease without losing a generation, set a new standard of care for patients and families, and forge a model of collaboration in biomedical research. The Institute provides high-level care and treatment for patients affected by Alzheimer's disease, dementia, and related disorders. In addition, the Institute offers extensive support services for families and many unique and rewarding research opportunities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4088/PCC.19alz02544 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Previous studies have shown that carriage of the VEGF 1154A (rs1570360) and the VEGF 2578C (rs699947) alleles may confer a protective effect on the development of Alzheimer's disease (AD). However, it is unknown if these associations are APOE-dependent and whether they can be observed in asymptomatic individuals with varying levels of amyloid pathology. The aim of this study is to determine whether interactions between the APOE ε4 allele, VEGF 1154A, and VEGF 2578C are associated with amyloid load in cognitively unimpaired (CU) older adults.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Background: Plasma tau phosphorylated at threonine 231 (p-tau231) is a promising novel biomarker of emerging Alzheimer's disease (AD) pathology. We aimed to characterize cross-sectional and longitudinal plasma p-tau231 measurements and estimated ages of biomarker onset in an exceptionally large number of presenilin (PSEN1) E280A (Glu280Ala) mutation carriers and age-matched non-carriers from the Colombian autosomal dominant Alzheimer's disease kindred.
Method: We included a cohort of 722 PSEN1 E280A mutation carriers (mean age 36.
Biomarkers.
Alzheimers Dement
December 2024
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Background: In this pilot study, the diagnostic agreement for sleep biomarker-based neurodegenerative disorder (NDD) risk probabilities was evaluated in patients with Alzheimer's disease dementia (AD), Lewy body disease (LBD), mild cognitive impairment (MCI), and controls (CG) with a Mini-Mental State Exam scores ≥28.
Methods: Sleep biomarkers recorded with the Sleep Profiler (Advanced Brain Monitoring, Inc.) were used as inputs to a 4-class machine learning algorithm trained to assign NDD risk probabilities to AD=27, LBD=19, isolated REM sleep behavior disorder=15, and CG=58.
Background: Currently there is no way to determine if archived cerebrospinal fluid (CSF) specimens have been properly handled and can be considered suitable for research purposes. Transthyretin (TTR) is abundant in CSF and undergoes a redox reaction that shifts its native proteoform into an S-cysteinylated form. This reaction proceeds spontaneously ex vivo when CSF is thawed, but ceases at storage temperatures of -80°C.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
Background: There is an urgent need for accurate and validated methods to measure plasma phosphorylated tau (p-Tau) biomarkers in Alzheimer´s disease (AD). Here we compared the performance of newly developed plasma ALZpath p-Tau217 assay to other established p-Tau assays such as Lilly p-Tau217 and Lilly p-Tau181.
Method: We included 72 participants from the Arizona Study of Aging and Neurodegenerative Disorders cohort, where we analysed antemortem collected plasma samples with ALZpath p-Tau217 as well as Lilly p-Tau217 and p-Tau181.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!